Table 1 Baseline demographic and clinical characteristics
From: Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies
|  | KW-2478 dose level (mg m–2) |  | ||||||
|---|---|---|---|---|---|---|---|---|
Characteristic | 14 ( n =3) | 28 ( n =3) | 47 ( n =3) | 71 ( n =3) | 99 ( n =3) | 132 ( n =6) | 176 ( n =6) | Total ( N =27) |
Mean age (years) (range) | 64.3 (58–68) | 70.0 (66–74) | 64.3 (63–65) | 66.7 (55–75) | 57.0 (48–62) | 60.7 (55–65) | 59.7 (52–69) | 62.6 (48–75) |
Mean BSA (m2) (range) | 1.7 (1.7–1.8) | 1.8 (1.6–2.1) | 1.9 (1.8–2.0) | 1.9 (1.6–2.2) | 2.0 (1.9–2.0) | 2.0 (1.8–2.1) | 1.9 (1.6–2.1) | 1.9 (1.6–2.2) |
Gender, n (%) | ||||||||
Male | 1 (33.3) | 1 (33.3) | 2 (66.7) | 2 (66.7) | 2 (66.7) | 5 (83.3) | 4 (66.7) | 17 (63.0) |
Female | 2 (66.7) | 2 (66.7) | 1 (33.3) | 1 (33.3) | 1 (33.3) | 1 (16.7) | 2 (33.3) | 10 (37.0) |
Race, n (%) | ||||||||
Caucasian | 3 (100.0) | 3 (100.0) | 3 (100.0) | 3 (100.0) | 3 (100.0) | 5 (83.3) | 6 (100.0) | 26 (96.3) |
Asian | 0 | 0 | 0 | 0 | 0 | 1 (16.7) | 0 | 1 (3.7) |
Disease, n (%) | ||||||||
MM | 3 (100.0) | 3 (100.0) | 3 (100.0) | 3 (100.0) | 2 (66.7) | 4 (66.7) | 4 (66.7) | 22 (81.5) |
NHL | 0 | 0 | 0 | 0 | 1 (33.3) | 2 (33.3) | 2 (33.3) | 5 (18.5) |
ECOG performance status, n (%) | ||||||||
0 | 2 (66.7) | 1 (33.3) | 2 (66.7) | 2 (66.7) | 3 (100.0) | 4 (66.7) | 4 (66.7) | 18 (66.7) |
1 | 1 (33.3) | 1 (33.3) | 1 (33.3) | 0 | 0 | 2 (33.3) | 1 (16.7) | 6 (22.2) |
2 | 0 | 1 (33.3) | 0 | 1 (33.3) | 0 | 0 | 1 (16.7) | 3 (11.1) |
